Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature

We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research